kabutan

Cuorips Inc.(4894) Summary

4894
TSE Growth
Cuorips Inc.
6,030
JPY
-50
(-0.82%)
Dec 5, 12:46 pm JST
38.87
USD
Dec 4, 10:46 pm EST
Result
PTS
outside of trading hours
5,984
Dec 5, 12:44 pm JST
Summary Chart Historical News Financial Result
PER
PBR
9.65
Yield
ー%
Margin Trading Ratio
306.76
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
6,070 JPY 39.12 USD
Previous Close Dec 4
6,080 JPY 39.13 USD
High Dec 5, 9:00 am
6,070 JPY 39.13 USD
Low Dec 5, 9:24 am
5,940 JPY 38.27 USD
Volume
61,000
Trading Value
0.37B JPY 2.36M USD
VWAP
6004.31 JPY 38.71 USD
Minimum Trading Value
603,000 JPY 3,887 USD
Market Cap
0.05T JPY 0.32B USD
Number of Trades
208
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
911
1-Year High Apr 10, 2025
10,530
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 100 668,900 6689.00
Nov 21, 2025 100 668,500 6685.00
Nov 14, 2025 0 678,700
Nov 7, 2025 0 677,800
Oct 31, 2025 1,400 678,200 484.43
Company Profile
Cuorips Inc. specializes in the development and commercialization of iPS cell-derived cardiomyocyte sheets.
Sector
Pharmaceuticals
Cuorips Inc. focuses on the development and commercialization of human iPS cell-derived cardiomyocyte sheets, working towards the practical application of regenerative medicine products. Through collaborative research with Osaka University and partnerships with major pharmaceutical companies, Cuorips has established advanced cell cultivation techniques. The company's products are expected to improve cardiac function and aid recovery from heart failure in patients with severe cardiac conditions. Utilizing its proprietary commercial cell culture and processing facility "CLiC-1", Cuorips also engages in Contract Development and Manufacturing Organization (CDMO) services and cell culture supernatant businesses. The CDMO services include development support and contract manufacturing, providing various cells as raw materials. The cell culture supernatant business effectively utilizes the liquid byproduct from the cell cultivation process. Cuorips aims to realize a wide range of regenerative medicine technologies, including the development of new catheter-based treatments and research on in vivo regeneration factor inducers.